850005-10-6

Basic information

• Product Name: 5-CHLORO-N-HYDROXY-2-METHYL-BENZAMIDINE
• Synonyms: 5-CHLORO-N-HYDROXY-2-METHYL-BENZAMIDINE;5-chloro-N-hydroxy-2-methylBenzenecarboximidamide
• CAS NO: 850005-10-6
• Molecular Formula: C₈H₉ClN₂O
• Molecular Weight: 184.62
• Mol File: 850005-10-6.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-CHLORO-N-HYDROXY-2-METHYL-BENZAMIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-CHLORO-N-HYDROXY-2-METHYL-BENZAMIDINE(850005-10-6)
• EPA Substance Registry System: 5-CHLORO-N-HYDROXY-2-METHYL-BENZAMIDINE(850005-10-6)

Safety Data

• Hazardous Substances Data: 850005-10-6(Hazardous Substances Data)

Upstream product

• 50712-70-4 5-chloro-2-methylbenzonitrile 

Downstream Products

• 850004-80-7 3-(2-methyl-5-chlorophenyl)-5-(4-(2-methylpropyl)phenyl)-1,2,4-oxadiazole 

Relevant articles and documents

PIPERIDINYLPYRAZOLOPYRIMIDINONES AND THEIR USE

The present application relates to novel substituted piperidinylpyrazolopyrimidinones, to processes for their preparation, the compounds for use alone or in combinations in a method for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of acute and recurrent bleeding in patients with or without underlying hereditary or acquired hemostatic disorders, wherein the bleeding is associated with a disease or medical intervention selected from the group consisting of heavy menstrual bleeding, postpartum hemorrhage, hemorrhagic shock, hemorrhagic cystitis, gastrointestinal hemorrhage, trauma, surgery, transplantation, stroke, liver diseases, hereditary angioedema, nosebleed, and synovitis and cartilage damage following hemarthrosis.

SUBSTITUTED OXADIAZOLE COMPOUNDS AND THEIR USE AS S1P1 AGONISTS

Disclosed are compounds of Formula (I): [PLEASE INSERT CHEMICAL STRUCTURE HERE] or stereoisomers, N-oxides, salts, or prodrugs thereof; wherein: Ring A is phenyl or 5- to 6-membered heteroaryl; (i) R1 and R2 are independently C1-C4 alkyl; or (ii) R1 and R

3,5-ARYL, HETEROARYL OR CYCLOALKYL SUBSTITUTED-1,2,4-OXADIAZOLES AS S1P RECEPTOR AGONISTS

The present invention encompasses compounds of Formula I: (I) as well as the pharmaceutically acceptable salts thereof. The compounds are useful for treating immune mediated diseases and conditions, such as bone marrow, organ and tissue transplant rejecti

NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS

The present invention relates to novel compounds of formula (I) wherein W, n, X and W’ are defined in the description; invention compounds are modulators of metabotropic glutamate receptors - subtype 5 (“mGluR5”) which are useful for the treatment of central nervous system disorders as well as other disorders modulated by mGluR5 receptors.